SPCG-15
Surgery versus radiotherapy for locally advanced prostate cancer
SPCG-15 is a prospective, multi-centre, open-label, randomized phase III trial including 1,200 patients at more than 20 hospitals in the Nordic countries. Patients are randomized to either standard (radiotherapy) or experimental (surgical) treatment for prostate cancer that grows outside the prostate capsule but has not yet spread to other organs. The primary endpoint is cause-specific survival. Secondary endpoints include metastasis-free and overall survival, quality-of-life, functional outcomes, and health-services requirements. Each subject will be followed up for a minimum of 20 years.